NanoViricides (NNVC) News Today $1.46 -0.14 (-8.75%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.47 +0.01 (+0.41%) As of 07/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NNVC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period NanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15 at 12:42 PM | proactiveinvestors.comNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPoxJuly 15 at 11:52 AM | finance.yahoo.comNanoViricides nears completion of clinical trial design for MPox treatmentJuly 14 at 8:52 AM | proactiveinvestors.comAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricidesJuly 14 at 7:42 AM | markets.businessinsider.comNanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health CaseJuly 7, 2025 | theglobeandmail.comNanoViricides advances antiviral candidate NV-387 into Phase 2 trials for MpoxJuly 2, 2025 | proactiveinvestors.comNanoViricides Inc.June 19, 2025 | barrons.comNanoViricides touts antiviral NV-387 as tool against new COVID variantJune 18, 2025 | proactiveinvestors.comNanoViricides measles drug development animal study imminentJune 4, 2025 | msn.comNanoViricides commissions animal study of broad-spectrum antiviral for measlesJune 4, 2025 | proactiveinvestors.comNanoViricides president backs FDA's targeted COVID booster policy shiftMay 22, 2025 | proactiveinvestors.comNanoViricides advances NV-387 antiviral program, eyes Phase II trials for MpoxMay 16, 2025 | proactiveinvestors.comNanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the SolutionMay 14, 2025 | finanznachrichten.deNanoViricides progresses antiviral portfolio as measles and MPox threats riseMay 14, 2025 | proactiveinvestors.comNanoViricides wins ethics approval for Phase II Mpox drug trial in DRCMay 8, 2025 | proactiveinvestors.comNanoViricides, Inc. Announces Participation in the D. ...May 5, 2025 | gurufocus.comNanoViricides advances measles drug development amid rising US casesApril 29, 2025 | proactiveinvestors.comNanoViricides evaluating antiviral drug NV-387 for measles treatmentApril 14, 2025 | proactiveinvestors.comNanoViricides unaffected by US tariff turmoil, says CFOApril 5, 2025 | proactiveinvestors.comNanoViricides eyes role in US bird flu fight as USDA unveils $100M initiativeMarch 28, 2025 | proactiveinvestors.comNanoViricides says business unaffected by US tariffs, highlights antiviral pipelineMarch 11, 2025 | proactiveinvestors.comNanoViricides says business unaffected by US tariffs, highlights antiviral pipelineMarch 11, 2025 | proactiveinvestors.comNanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreakMarch 4, 2025 | proactiveinvestors.comSmall cap headlines: EnWave, NanoViricides, GoviEx, TNR GoldFebruary 21, 2025 | proactiveinvestors.comNanoViricides reports Q2 EPS (14c) vs. (18c) last yearFebruary 19, 2025 | markets.businessinsider.comNanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trialsFebruary 19, 2025 | proactiveinvestors.comNanoViricides announces readiness to combat bird flu with antiviral drug NV-387February 11, 2025 | proactiveinvestors.comNanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387February 4, 2025 | proactiveinvestors.comNanoViricides warns of bird flu pandemic as outbreak spreads in MassachusettsJanuary 31, 2025 | proactiveinvestors.comNanoViricides taps clinical research organization for Phase II trial of NV-387January 27, 2025 | proactiveinvestors.comNanoViricides CEO discusses NV-387's broad spectrum promise - ICYMIJanuary 11, 2025 | proactiveinvestors.comNanoViricides: Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum AntiviralsJanuary 8, 2025 | finanznachrichten.deNanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threatsJanuary 8, 2025 | proactiveinvestors.comNanoViricides sees NV-387 as a key defense against bird flu pandemicDecember 23, 2024 | proactiveinvestors.comNanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North AmericaDecember 6, 2024 | proactiveinvestors.comNanoViricides pushes NV-387 to Phase II trialsNovember 15, 2024 | proactiveinvestors.comNanoViricides Inc. (NNVC): Best Nanotech Penny Stock to BuyOctober 14, 2024 | msn.comInvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR SummitOctober 8, 2024 | msn.comNanoViricides prepares for Phase II trials for antiviral NV-387September 30, 2024 | proactiveinvestors.comNanoviricides (AMEX:NNVC) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comNanoViricides expands antiviral drug pipeline with TheraCour Pharma agreementSeptember 26, 2024 | proactiveinvestors.comNanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMISeptember 14, 2024 | proactiveinvestors.comNanoViricides exploring emergency protocol to evaluate NV-387 for MPOXAugust 26, 2024 | proactiveinvestors.comNanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387August 19, 2024 | proactiveinvestors.comNanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387August 8, 2024 | proactiveinvestors.comFrontier Biotechnologies Inc. (688221.SS)August 8, 2024 | finance.yahoo.comNanoViricides' lead asset for broad spectrum efficacy wins praise in industry reportsAugust 1, 2024 | proactiveinvestors.comNNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral TherapyJuly 31, 2024 | msn.comNanoViricides spotlights lead drug candidate's potential as COVID therapyJuly 24, 2024 | proactiveinvestors.comNanoViricides discusses lead program and next stepsJuly 11, 2024 | proactiveinvestors.com Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address NNVC Media Mentions By Week NNVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NNVC News Sentiment▼0.760.97▲Average Medical News Sentiment NNVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NNVC Articles This Week▼40▲NNVC Articles Average Week Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Invivyd News Cellectis News Adagene News Oncolytics Biotech News Climb Bio News Elutia News Entera Bio News TScan Therapeutics News eXoZymes News Cabaletta Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NNVC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NNVC Stock Alerts